SISVEL
14.12.2022 10:02:01 CET | Business Wire | Press release
Sisvel International S.A. (“Sisvel”) today announced the launch of its 5G Multimode (5G MM) Licensing Program.
The 5G MM Program offers a single solution to license Standard Essential Patents (SEPs) for the use of cellular standards up to and including 5G. The license offer will be focused on consumer electronic products, and includes the 2G, 3G, 4G and 5G SEPs owned by 14 founding companies: Alfred Consulting LLC, Intellectual Discovery Co., Ltd., JVCKENWOOD Corporation, KDDI Corporation, Koninklijke KPN N.V., Mitsubishi Electric Corporation, Siemens Aktiengesellschaft, SK Telecom Co., Ltd., Technology in Ariscale, LLC, Telefónica S.A., TIM S.p.A., Wilus Inc., Wireless Innovations, LLC and Sisvel. Sisvel is also continuing discussions with various additional companies that may have an interest in joining the pool.
“Sisvel’s 5G MM program will be the only cellular patent pool directed to the wireless market for consumer electronic products, with Via Licensing having announced its exit from the space. Having a single patent pool will help eliminate confusion in the market and increase cellular licensing efficiencies for implementers and licensors alike,” comments Donald Chan, the program manager of the Sisvel 5G MM Licensing Program.
“Sisvel’s 5G MM Program represents an efficient and competitive license offer for the consumer electronics market. It will grant freedom-to-operate to implementers and, in turn, generate royalty revenue to the group of innovators who helped pave the way for the connected world we enjoy and see improving every day. It is at the heart of Sisvel to make sure these innovators are rewarded for their hard work and assumed risk, which is unavoidable when you invest in R&D, so that they can continue inventing the products that will improve our lives,” states Mattia Fogliacco, President of the Sisvel Group.
With the 5G MM Program, Sisvel offers an efficient and transparent way for implementers to access the relevant SEPs of the participating patent owner under fair and reasonable terms. Sisvel has the right to grant non-exclusive licenses under all cellular standard essential patents, including 2G, 3G, 4G and 5G, owned and/or controlled by the participating patent owners.
The 5G MM Program remains open to additional patent owners with relevant patents. Sisvel invites all parties that have patents they believe to be essential to the cellular standards to join the patent pool and contact Sisvel to submit those patent(s) for an evaluation by the program’s designated, independent evaluators.
Further information about the terms and conditions of the 5G MM licensing offer is available on Sisvel’s website: https://www.sisvel.com/licensing-programs/wireless-communications/5g-multimode/patent-pool/introduction. For more details you may contact Sisvel at the following e-mail address MC@sisvel.com
About Sisvel
Sisvel International S.A. is the holding company of the Sisvel Group. Sisvel is a world leader in fostering innovation and managing IP. The group identifies, evaluates and maximizes the value of IP assets for its partners around the world, providing firms with a revenue stream which can be reinvested in innovation for the generation of future revenues. Sisvel has 40 years’ experience in the management of successful patent portfolios, including those relating to audio compression standards (MP3 and MPEG audio), as well as broadcasting and digital terrestrial television standards maintained by the Digital Video Broadcasting Project. Currently Sisvel operates patent pools and joint licensing programs in the fields of mobile communication, wireless local area networking 802.11, video coding and digital video broadcasting.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005132/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom